[Application and prospect of PD-1 or PD-L1 inhibitor in advanced hepatocellular carcinoma].

Mao, J; Yan, Q; Shen, Z H; Sun, X; Zheng, S S

Mao, J; Yan, Q; Shen, Z H; Sun, X; Zheng, S S.

Afiliação

Mao J; Department of General Surgery,Huzhou Hospital,College of Medicine,Zhejiang University,Huzhou 313003,Zhejiang Province,China.
Yan Q; Department of General Surgery,Huzhou Hospital,College of Medicine,Zhejiang University,Huzhou 313003,Zhejiang Province,China.
Shen ZH; Department of General Surgery,Huzhou Hospital,College of Medicine,Zhejiang University,Huzhou 313003,Zhejiang Province,China.
Sun X; Department of General Surgery,Huzhou Hospital,College of Medicine,Zhejiang University,Huzhou 313003,Zhejiang Province,China.
Zheng SS; Department of Hepatobiliary and Pancreatic Surgery,the First Affiliated Hospital,College of Medicine,Zhejiang University,Hangzhou 310003,China.

Zhonghua Wai Ke Za Zhi ; 59(10): 875-880, 2021 Oct 01.

Article em Zh | MEDLINE | ID: mdl-34619915

Assuntos

Carcinoma Hepatocelular; Neoplasias Hepáticas; Carcinoma Hepatocelular/tratamento farmacológico; Humanos; Inibidores de Checkpoint Imunológico; Neoplasias Hepáticas/tratamento farmacológico; Recidiva Local de Neoplasia; Receptor de Morte Celular Programada 1

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Carcinoma Hepatocelular / Neoplasias Hepáticas Limite: Humans Idioma: Zh Revista: Zhonghua Wai Ke Za Zhi Ano de publicação: 2021 Tipo de documento: Article País de afiliação: China

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google